Physician-Scientist Pipeline for Pediatric Rheumatology: The Current Landscape and Future Perspectives

Ekemini A Ogbu1,2,3, Linda T Hiraki4,5, Mara L Becker6

  • 1Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Insights

Pediatric rheumatology has advanced significantly, but the physician-scientist pipeline is declining. This review examines challenges and future perspectives for this critical role in treating childhood inflammatory diseases.

Area of Science:

  • Pediatric Rheumatology
  • Systemic Inflammatory Diseases
  • Medical Research

Background:

  • The field of pediatric rheumatology has seen exponential growth over 50 years.
  • Advances in understanding rheumatic conditions and novel therapeutics have improved care for children with chronic inflammatory diseases.
  • Physician-scientists are crucial for translating research from bench to bedside.

Purpose of the Study:

  • To review the current landscape of the physician-scientist pipeline in pediatric rheumatology.
  • To identify challenges facing the declining pipeline of pediatric rheumatologists.
  • To discuss future perspectives for sustaining the physician-scientist workforce.

Main Methods:

  • Review of the current state of the physician-scientist pipeline in pediatric rheumatology.
  • Analysis of factors contributing to the decline in physician-scientists.
  • Discussion of future strategies and perspectives.

Main Results:

  • The physician-scientist pipeline in pediatric rheumatology is facing a decline.
  • Several factors contribute to the "endangered species" status of these crucial researchers.
  • The 50th anniversary of the specialty highlights the need to address pipeline issues.

Conclusions:

  • Maintaining a robust physician-scientist pipeline is essential for continued progress in pediatric rheumatology.
  • Addressing the challenges is critical for the future of treating pediatric systemic inflammatory diseases.
  • Future perspectives are needed to ensure the sustainability of physician-scientists in the field.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
409
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
404
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
960
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
552